Amneal Metformin Recall Lawsuit

What’s the Problem?

Amneal was notified by the U.S. Food & Drug Administration (FDA) that at least 7 lots of its metformin had tested above acceptable limits for N-Nitrosodimethylamine (NDMA), a probable human carcinogen (cancer-causing substance).

FDA recommended the recall of all 7 lots of the metformin, but “out of an abundance of caution,” Amneal decided to extend the recall to all lots within expiry of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg.

The recalled metformin was distributed nationwide to Wholesalers, Distributors, Retailers and Repackagers. Click on the FDA Recall Notice to view all lot numbers affected by the recall.

Amneal is notifying its direct customers via UPS Standard Overnight mail and is arranging for return of all the recalled metformin. Anyone with an existing inventory of the product should quarantine the recalled lots immediately, FDA said. This recall began on May 29, 2020.

Do I Have an Amneal Metformin Recall Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Amneal Metformin Recall Lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.

If you or a loved one has been injured by metformin, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.